Thank all and afternoon, like pandemic. as the to I and partners thank Road driving Good you, joining our Silk immense against us. physician the team Marissa. adoption by for of you the COVID-XX start the we of would headwinds car efforts forward of continue acknowledging
and procedures quarter difficult third system like The elective for the hospital a TCAR. inpatient was U.S. specifically period for
variant a impact across in As the pandemic staffing XX% sales COVID-XX significant $XX.X July, we carried environment greater more million percentage a our created a and signaled disruption our consequences year-over-year of had Delta mid-September, and over shortages for reflecting business growth. challenges, these into have hospitals to we QX its quarter, recognized back Despite drove overall in than revenue in regions. which capacity QX. from the we and constraints, The complex in expected
range a we As shortly. our full million. will our XXXX outlook to Lucas a our more are on provide discuss these to and guidance $XX of result revising dynamics, commentary of million financial revenue $XXX results
and regions are are business, been at presenting, executing our related headwinds where have are we In patients strategy. and have view, confident overwhelmingly that our we are transient. rates hospitals our in we vaccination As look the facing and high, capacity, we pandemic on are
TCAR, continue procedures. TCAR physicians country, fact, trained performing was the albeit a In areas Delta in total with hospitalization in fewer Even recent the hardest the during perform number to soaring hit despite QX. in of line physicians COVID QX the wave, of
a stark of quarter. regions data TCAR regional during procedures in across parts COVID the analysis and third harder-hit of between between the specific relationship Our the contrast hospitalizations shows rate the utilization versus to analyze us less country. also procedures allows impacted This
heavily excited Delta and the the offense. pandemic that underlying procedures said back about performance as our the regions, over higher and for Western QX And growth regions, and rates opportunity For of just for did Southern this future physician Northeast, penetration Midwestern the today, in in months In was the On per both QX. view an variant, Mid-Atlantic impacted call, areas coming ago. our business roughly we and business fell encouraging three procedures as example, on of we and growth versus the with prospects our In by remain XX%. wanes. totality, roughly fewer analysis vaccination offers last as per year we XX% our hospitalizations, grew physician
which is are in COVID-XX the severe in and for spikes hopeful XX over a the without months. have managed hospitalizations seen endemic that future last we We
carotid on our pleased by We throughout exceed As artery Today, is of people end With XXXX the our standard remain of training to goal new our to as track committed the we commercial are least that, in to disease. execution. the U.S. that confidently that XXX and one drive announce as establishing now, at are and XXXX strategic for the priority physicians investing we in of number pandemic, we beyond. growth in as year. are have the as new of TCAR care we ever will and programs
sales our year. exceed target We at by territory territories of of to least XX track end are on the also the expansion
carotid measured healthcare effects to utilization and Importantly, the quartile procedures This in physician continues system. pandemic remains by growth diagnoses true training, grow of across trained overall against per and as the procedures denominator each physicians. even from overall continued dampening despite on and time the
continually for programs day. base We procedural expansion initiatives physician CEA to growing stroke the up actively positioned well clinical every We are curve, our a TCAR, field we value increase across and unshaken team, evidence single physicians COVID, to by remain of patients hospitals impact to and its building versus fruition of value adoption given bring of share the physicians and the reducing risk relationships to of drive devastating are for long-term the training TCAR. and
patients. Vascular with possible Moving The for clinical morphologies. across affirms disease Meeting surgical Annual TCAR's on approach risk year, equivalent patients the delivering preventing strategic broad independent due death to August, risk give CEA, ipsilateral matched already risk the risk we clearly CEA our is nerve a standard illustrated second an MI, stroke one reduced TCAR. surgical Silk Road, in in TCAR should with stroke, long At less at confidence and in anatomies benefits for XX,XXX understand TCAR. our the while what expanded standard outlined, surgical analysis invasive adoption XXXX risk standard significantly were from carotid paired patients, priority range use a over disease stroke preparing over propensity patient in With proven plus perioperative at lives cranial its of safely of study for stroke or driving impact versus through for injury and the year Conclusions be in the study over efficiencies term. risk artery benefits to of patients satisfaction on of us advancing and expansion.
FDA And the expand them toward surgical additional Importantly, population. provide we progress to are patient into risk FDA indications standard the data. with that we requested for TCAR making over, receiving approval
still track information additional are decision second as since submitted the an FDA we receive have XXXX. to believe that an quarter by and on We that we amendment, of
with training label remain a our post-market preparation standard coverage, includes chain surgical CMS continue augmenting to and field commercial about and a for expansion, bringing launch. This on for for physician the and community Our teams enthusiastic planning engaging supply materials. to with TCAR level-playing the risk programs we and CEA, prepare and study, reimbursement marketing opportunity
Regarding our additional long-term drivers. growth
-- disease to objectives products, introduce and TCAR make states excuse expand me. and We transcarotid innovate new disease on in continue neurovascular new and international to states, markets into progress improved therapies carotid cardiac
in are or transcarotid feasibility in active we site study. embolectomy our processes example, for initiation night one For neuroprotection
and head TAM Our R&D globally. and market $X.X numerous developing remain deepening unlock TCAR programs We with committed grow. continue billion while our the lead associated the initiatives to exporting in with capabilities in the product and working to expanding significant count, clinical U.S. TCAR to
earnings We half acknowledge were second impacted results In revenue reflect environment. many provide with in challenges the the operating QX. our our expect surprised further in our on and system the we U.S. closing, by we future calls. variant severity Delta the will which initiatives hospital of speed these that the updates And to on
clear. However, by the encouraged we to of are fundamentals begins our as the environment business
today, sit here continue we signs As are seeing we of which we improvement, closely monitor. early to
transparent also regarding expectations. remain ongoing We to to intend impact its and our the pandemic
Chief by Most importantly, for call posed Buchanan, We Operating of will our over XXXX remains Silk our excitement to remains long-term reaccelerate and of stronger than our unhindered. dedication the to Road's ever. Financial Officer COVID challenges Chief to for response and incredibly the and turn are patients value With now into the alike proud Lucas to opportunity the TCAR Officer. that, I hospitals
